Back to results
US 2022/0016208 A1Published application
Methods and agents to treat infertility in females
AssigneeUniversity of Cincinnati
InventorsLori R. Bernstein, Tom Thompson
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Cincinnati
InventorsLori R. Bernstein, Tom Thompson
Estimating the term…
Described are novel female fertility therapies. A first aspect of the invention is directed to therapies that include FSH lowering methodologies to prevent and/or treat egg infertility. A second aspect of the invention is directed to agents that bind to activin, bind to receptors that bind activin, or that otherwise disrupt activin signaling (collectively referred to herein as “activin pathway modifier agents” or “APM agents”) and methods of utilizing these agents to prevent and/or treat egg infertility. A third aspect of the invention is directed to methods of administering an effective amount of an APM agent to a subject to increase oocyte yield and/or ovarian reserve. All three aspects of the invention may be used in humans and in animals. Additional aspects of the invention include therapeutic drug kits for treatment of humans and animals based on the methodologies described above.
A method of treating and/or reducing the incidence of infertility, miscarriages, trisomic pregnancies, or birth defects in a female subject, wherein said infertility, miscarriages, trisomic pregnancies, or birth defects result from oocyte aneuploidy, embryonic aneuploidy, and/or fetal aneuploidy, said method comprising administering to a female subject at least one FSH lowering agent or activin pathway modifying agent;
A method of increasing oocyte production in a female subject comprising administering to the subject at least one FSH lowering agent or activin pathway modifying agent;
A kit for preventing or treating egg infertility in a subject comprising at least one of a FSH lowering agent or an APM agent in an amount effective to prevent or treat the egg fertility.
A kit for increasing oocyte production in a subject comprising at least one FSH lowering agent or an APM agent in an amount effective to increase oocyte production.
Dependencies are inferred from the claim text.